Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Tyrosine kinase inhibitor levels matter in treating chronic GVHD

Bone Marrow Transplantation volume 54, pages 1141–1144 (2019)Cite this article

Subjects

Key points

  • We observed a possible concentration effect relationship for nilotinib on resolution of chronic Graft versus Host disease.

  • These data suggest therapeutic drug monitoring might be useful for patients receiving tyrosine kinase inhibitors for chronic GVHD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

References

  1. Chabannon C, Kuball J, Bondanza A, Dazzi F, Pedrazzoli P, Toubert A, et al. Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies. Sci Transl Med. 2018;10:436–46.

    Article  Google Scholar 

  2. Magro L, Mohty M, Catteau B, Coiteux V, Chevallier P, Terriou L, et al. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood. 2009;114:719–22.

    Article  CAS  Google Scholar 

  3. Magro L, Catteau B, Coiteux V, Bruno B, Jouet JP, Yakoub-Agha I. Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD. Bone Marrow Transplant. 2008;42:757–60.

    Article  CAS  Google Scholar 

  4. Olivieri A, Locatelli F, Zecca M, Sanna A, Cimminiello M, Raimondi R, et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood . 2009;114:709–18.

    Article  CAS  Google Scholar 

  5. de Masson A, Bouaziz JD, Peffault de Latour R, Wittnebel S, Ribaud P, Rubio MT, et al. Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD. Blood . 2012;120:5089–90.

    Article  Google Scholar 

  6. Arai S, Pidala J, Pusic I, Chai X, Jaglowski S, Khera N, et al. A randomized phase II crossover study of imatinib or rituximab for cutaneous sclerosis after hematopoietic cell transplantation. Clin Cancer Res. 2015;22:319–27.

  7. Chen GL, Carpenter PA, Broady R, Gregory TK, Johnston LJ, Storer BE, et al. Anti-platelet-derived growth factor receptor alpha chain antibodies predict for response to nilotinib in steroid-refractory or -dependent chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2018;24:373–80.

    Article  CAS  Google Scholar 

  8. van der Wagen L, Te Boome L, Schiffler M, Nijhof I, Schoordijk M, van Dorp S, et al. Prospective evaluation of sequential treatment of sclerotic chronic graft versus host disease with rituximab and nilotinib. Bone Marrow Transplant. 2018;53;1255–62.

    Article  CAS  Google Scholar 

  9. Verheijen RB, Yu H, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR. Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology. Clin Pharmacol Ther. 2017;102:765–76.

    Article  Google Scholar 

  10. Herbrink M, de Vries N, Rosing H, Huitema AD, Nuijen B, Schellens JH, et al. Quantification of 11 therapeutic kinase inhibitors in human plasma for therapeutic drug monitoring using liquid chromatography coupled with tandem mass spectrometry. Ther Drug Monit. 2016;38:649–56.

    Article  CAS  Google Scholar 

  11. Wang Y, Chia YL, Nedelman J, Schran H, Mahon FX, Molimard M. A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times. Ther Drug Monit. 2009;31:579–84.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

We thank Novartis and Roche for kindly providing study medication. This work was further supported in part by grants from the Dutch Cancer Society to LvdW: KWF-UU 2011-5250 and to JK KWF-UU 2010-4669, 2013-6426, 2014-6790, and 2015-7601.

Author contributions

LvdW, AH, and JK designed the study. LvdW and JK performed the prospective clinical trial. JJ and AH performed the nilotinib concentration measurements. LvdW, JJ, JJB, AH, and JK analyzed the data. All authors interpreted the data and wrote the manuscript.

Author information

Authors and Affiliations

  1. Department of Hematology, University Medical Center Utrecht, Room number Q05.4.301, PO Box 85500, Utrecht, GA, 3508, The Netherlands

    Lotte van der Wagen, Reinier Raijmakers, Eefke Petersen, Moniek de Witte & Jürgen Kuball

  2. Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

    Lotte van der Wagen, Jaap Jan Boelens & Jürgen Kuball

  3. Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands

    Julie Janssen & Alwin Huitema

  4. Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands

    Niels de Jong

  5. Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands

    Mar Bellido

  6. Department of Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands

    Ellen Meijer

  7. Department of Hematology, Radboud Medical Center, Nijmegen, The Netherlands

    Brigitte Bär

  8. Department of Pediatrics, Stem Cell Transplant and Cellular Therapies Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA

    Jaap Jan Boelens

  9. Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands

    Alwin Huitema

Authors
  1. Lotte van der Wagen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julie Janssen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Reinier Raijmakers
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eefke Petersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Moniek de Witte
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Niels de Jong
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mar Bellido
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ellen Meijer
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Brigitte Bär
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jaap Jan Boelens
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Alwin Huitema
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Jürgen Kuball
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jürgen Kuball.

Ethics declarations

Conflict of interest

JK is cofounder and scientific advisor of GADETA. His work is partly supported by a grant from Novartis; however, Novartis had no part in the design, analysis, or interpretation of the data or the writing of the manuscript.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

van der Wagen, L., Janssen, J., Raijmakers, R. et al. Tyrosine kinase inhibitor levels matter in treating chronic GVHD. Bone Marrow Transplant 54, 1141–1144 (2019). https://doi.org/10.1038/s41409-018-0429-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-018-0429-5

This article is cited by

Search

Advanced search

Quick links